Cargando…
Complications of Lumbar Artificial Disc Replacement Compared to Fusion: Results From the Prospective, Randomized, Multicenter US Food and Drug Administration Investigational Device Exemption Study of the Charité Artificial Disc
BACKGROUND: Previous reports of lumbar total disc replacement (TDR) have described significant complications. The US Food and Drug Administration (FDA) investigational device exemption (IDE) study of the Charité artificial disc represents the first level I data comparison of TDR to fusion. METHODS:...
Autores principales: | Holt, Richard T., Majd, Mohammed E., Isaza, Jorge E., Blumenthal, Scott L., McAfee, Paul C., Guyer, Richard D., Hochschuler, Stephen H., Geisler, Fred H., Garcia, Rolando, Regan, John J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RRY Publications, LLC
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365564/ https://www.ncbi.nlm.nih.gov/pubmed/25802575 http://dx.doi.org/10.1016/SASJ-2006-0004-RR |
Ejemplares similares
-
The First 18 Months Following Food and Drug Administration Approval of Lumbar Total Disc Replacement in the United States: Reported Adverse Events Outside an Investigational Device Exemption Study Environment
por: Blumenthal, Scott L., et al.
Publicado: (2007) -
Prospective, Randomized, Multicenter FDA IDE Study of CHARITÉ Artificial Disc versus Lumbar Fusion: Effect at 5-year Follow-up of Prior Surgery and Prior Discectomy on Clinical Outcomes Following Lumbar Arthroplasty
por: Geisler, Fred H., et al.
Publicado: (2009) -
Kineflex lumbar artificial disc versus Charité lumbar total disc replacement for the treatment of degenerative disc disease: A randomized non-inferiority trial with minimum of 2 years’ follow-up
por: Pettine, Kenneth, et al.
Publicado: (2011) -
Analysis of adjacent segment reoperation after lumbar total disc replacement
por: Rainey, Scott, et al.
Publicado: (2012) -
ISASS Policy Statement – Lumbar Artificial Disc
por: Zigler, Jack, et al.
Publicado: (2015)